Citadel Advisors
HOWL icon

Citadel Advisors’s Werewolf Therapeutics HOWL Stock Holding History

Citadel Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,382
Closed -$6.33K – 14175
2026
Q1 		$8.64K Buy
+10,382
New +$7.11K ﹤0.01% 12776
2025
Q4 		– Sell
-154,534
Closed -$304K – 13238
2025
Q3 		$304K Buy
+154,534
New +$212K ﹤0.01% 10338
2024
Q4 		– Sell
-11,507
Closed -$23.5K – 14876
2024
Q3 		$24.4K Sell
11,507
-52,447
-82% -$119K ﹤0.01% 12620
2024
Q2 		$156K Buy
63,954
+60,881
+1,981% +$292K ﹤0.01% 10290
2024
Q1 		$19.9K Sell
3,073
-18,449
-86% -$108K ﹤0.01% 13020
2023
Q4 		$83.1K Buy
+21,522
New +$55K ﹤0.01% 11167
2023
Q1 		– Sell
-11,030
Closed -$22.6K – 15033
2022
Q4 		$22.6K Buy
+11,030
New +$28.9K ﹤0.01% 13044
2022
Q2 		– Sell
-20,144
Closed -$89K – 13376
2022
Q1 		$89K Buy
+20,144
New +$141K ﹤0.01% 12390

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citadel Advisors's HOWL Position: Q2 2026 in Review

Citadel Advisors sold out of Werewolf Therapeutics (HOWL) in Q2 2026, closing a stake of 10,382 shares — an estimated $6.33K sold.

Citadel Advisors first reported a position in HOWL in Q1 2022 and held it in 8 quarters. The position peaked at $304K in Q3 2025. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Citadel Advisors reported no remaining Werewolf Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 10,382 Werewolf Therapeutics shares in Q2 2026, an estimated $6.33K.
  • Citadel Advisors first reported a position in Werewolf Therapeutics in Q1 2022 and held it in 8 quarters.
  • Citadel Advisors's Werewolf Therapeutics position peaked at $304K in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.